Palliative treatment with oral Estracyte in disseminated prostatic carcinoma.
In Roswell Park Memorial Institute, between 1969 and 1974, a total of 32 patients with widespread metastasized carcinoma of the prostate were treated with oral Estracyt. Objectively demonstrable remissions were achieved in eight patients (8/32 equals 25%). Subjective improvement of their general condition was experienced by 15 patients (15/32 equals 47%). The toxicity of Estracyt manifests itself with gastrointestinal disorders, which in most cases are amenable to anti-emetic treatment.
D000284:Administration, Oral; D000368:Aged; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004961:Estramustine / Q000008:administration & dosage* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000008:administration & dosage*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D009588:Nitrogen Mustard Compounds; D004961:Estramustine